Aurinia Pharmaceuticals Company Top Insiders
AUPH Stock | USD 8.01 0.27 3.49% |
Aurinia Pharmaceuticals employs about 300 people. The company is managed by 16 executives with a total tenure of roughly 11 years, averaging almost 0.0 years of service per executive, having 18.75 employees per reported executive. Assessment of Aurinia Pharmaceuticals' management performance can provide insight into the firm performance.
Aurinia |
Aurinia Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0578) %, meaning that it created substantial loss on money invested by shareholders. Aurinia Pharmaceuticals' management efficiency ratios could be used to measure how well Aurinia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Aurinia Pharmaceuticals Workforce Comparison
Aurinia Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 6,638. Aurinia Pharmaceuticals holds roughly 300 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17. Aurinia Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aurinia Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aurinia Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aurinia Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aurinia Pharmaceuticals Notable Stakeholders
An Aurinia Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aurinia Pharmaceuticals often face trade-offs trying to please all of them. Aurinia Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aurinia Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter MBA | CEO President | Profile | |
Chris Hays | VP Marketing | Profile | |
Premchandran Ramiya | Senior Chain | Profile | |
Joseph CPA | Chief Officer | Profile | |
Ann Daus | Senior Quality | Profile | |
Andrea Christopher | Head Relations | Profile | |
Michael Martin | Chief Officer | Profile | |
Fran Lynch | Vice Sales | Profile | |
Matthew MBA | Executive Strategy | Profile | |
Sue Evans | Senior Affairs | Profile | |
Scott Habig | Chief Officer | Profile | |
Gregory MD | Chief Officer | Profile | |
MD DSc | Executive Development | Profile | |
Stephen Robertson | Executive Counsel | Profile | |
DeDe Sheel | Vice Relation | Profile | |
James Harrell | Head Relations | Profile |
About Aurinia Pharmaceuticals Management Performance
The success or failure of an entity such as Aurinia Pharmaceuticals often depends on how effective the management is. Aurinia Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aurinia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aurinia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 300 people.
Aurinia Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Aurinia Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aurinia Pharmaceuticals within its industry.Aurinia Pharmaceuticals Manpower Efficiency
Return on Aurinia Pharmaceuticals Manpower
Revenue Per Employee | 585K | |
Revenue Per Executive | 11M | |
Net Loss Per Employee | 260.1K | |
Net Loss Per Executive | 4.9M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 21.7M |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Transaction History View history of all your transactions and understand their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |